Back to Results
First PageMeta Content
Medicine / Immunology / Monoclonal antibodies / Clinical medicine / Biology / Immune system / Pathology / Biotechnology / IMAB362 / Cancer / Monoclonal antibody therapy / Antibody


Press release Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety Mainz, Germany, August 04, A clinical first-in-human Phase I multi center study with GANYMED’s monoclonal anti
Add to Reading List

Document Date: 2015-02-04 05:15:07


Open Document

File Size: 98,24 KB

Share Result on Facebook
UPDATE